14-Jan-2026
TipRanks (Mon, 12-Jan 9:50 PM ET)
Cabaletta Bio Sets 2026 Strategy for Rese-cel Expansion
TipRanks (Mon, 12-Jan 8:41 AM ET)
Cabaletta Bio Announces 2026 Strategic Priorities
Globe Newswire (Mon, 12-Jan 8:00 AM ET)
Business Wire (Mon, 12-Jan 7:30 AM ET)
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
Globe Newswire (Mon, 10-Nov 7:30 AM ET)
Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December
Globe Newswire (Tue, 4-Nov 8:00 AM ET)
Globe Newswire (Mon, 27-Oct 7:00 AM ET)
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
Cabaletta Bio trades on the NASDAQ stock market under the symbol CABA.
As of January 14, 2026, CABA stock price was flat at $2.15 with 899,386 million shares trading.
CABA has a beta of 4.18, meaning it tends to be more sensitive to market movements. CABA has a correlation of 0.36 to the broad based SPY ETF.
CABA has a market cap of $206.97 million. This is considered a Small Cap stock.
Last quarter Cabaletta Bio reported $0 in Revenue and -$.44 earnings per share. This fell short of revenue expectation by $-833,330 and exceeded earnings estimates by $.03.
In the last 3 years, CABA traded as high as $26.35 and as low as $.99.
The top ETF exchange traded funds that CABA belongs to (by Net Assets): VTI, VXF, IBB, IWC, PRFZ.
CABA has underperformed the market in the last year with a price return of -0.5% while the SPY ETF gained +20.0%. CABA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -13.7% and 0.0%, respectively, while the SPY returned +4.4% and +0.5%, respectively.
CABA support price is $2.06 and resistance is $2.24 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CABA shares will trade within this expected range on the day.